PMID: 15353872Sep 9, 2004Paper

The effects of octreotide in dilated cardiomyopathy: an open-label trial in 12 patients

Japanese Heart Journal
Namlk Kemal EryolAbdurrahman Oguzhan

Abstract

Octreotide, a somatostatin analogue, has been found effective in the treatment of acromegalic cardiomyopathy. We investigated whether intermittent octreotide therapy had beneficial effects in patients with ischemic or idiopathic dilated cardiomyopathy, which are refractory to conventional therapy. Twelve patients with ischemic or idiopathic dilated cardiomyopathy were enrolled in the study. In addition to conventional treatment, octreotide (first 50 microg and then 25 microg three times per day for 4 days) was administered and repeated after 1, 2, and 3 months. The patients were evaluated 3 times, before and immediately after the first treatment and after 3 months of treatment, using echocardiography, exercise stress testing, ambulatory ECG, right ventricular catheterization, cardiac enzymes, and the Minnesota living with heart failure questionnaire for quality of life. There were no significant changes in parameters after the first treatment. However, after 3 months of treatment, there were significant improvements in the left ventricular ejection fraction, left ventricular posterior wall thickness, hemodynamics, exercise capacity, and quality of life. Additionally, ischemic burden and the number of ventricular premature beats...Continue Reading

References

Nov 1, 1992·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·R Taylor, A D Waggoner
Dec 15, 1990·Annals of Internal Medicine·P ChansonJ Lubetzki
Jun 1, 1989·Journal of Molecular and Cellular Cardiology·S HiraiH Mashiba
Sep 1, 1989·The American Journal of Physiology·E M RichardsM I Phillips
Feb 1, 1985·British Heart Journal·S M DayS R Bloom
May 1, 1985·Metabolism: Clinical and Experimental·T Mountokalakis, M Levy
Jan 1, 1988·British Journal of Pharmacology·C I LinH L Wu
Feb 15, 1986·The American Journal of Cardiology·R B DevereuxN Reichek
Oct 1, 1984·International Journal of Cardiology·P A van den HeuvelA V Bruschke
Jul 1, 1994·European Journal of Pharmacology·X Y DuP R Saxena
Jan 25, 1996·The New England Journal of Medicine·S W LambertsL J Hofland
May 1, 1996·European Journal of Endocrinology·S J PadayattyP E Belchetz
Aug 1, 1996·Metabolism: Clinical and Experimental·G LombardiL Sacca
Apr 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T E JonassenJ S Petersen
Aug 19, 1999·The New England Journal of Medicine·R W Schrier, W T Abraham
Sep 1, 1999·Clinical Endocrinology·R C Jenkins, R J Ross
Sep 1, 1999·Clinical Endocrinology·F BroglioE Ghigo
Oct 21, 1999·The New England Journal of Medicine·J J Hunter, K R Chien
Mar 22, 2000·Journal of Endocrinological Investigation·A BensoE Ghigo

❮ Previous
Next ❯

Citations

Jan 26, 2018·Journal of Cardiovascular Development and Disease·Marco Luciani, Federica Del Monte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.